Status:
UNKNOWN
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Cardiotoxicity
Osteosarcoma
Eligibility:
All Genders
8-50 years
Brief Summary
using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2\* mapping and late gadolinium enhancement(LGE) sequences, as well as...
Detailed Description
Osteosarcoma is the most common primary malignant bone tumor in children and young adults and accounts for 5% of all pediatric malignancies. The long-standing chemotherapy regimen of doxorubicin and c...
Eligibility Criteria
Inclusion
- All chemotherapy naive patients whose biopsy results show high grade osteosarcoma undergoing an anthracycline agent as part of their chemotherapy regimen
- Informed consent has been signed
Exclusion
- Strict contraindications to contrast-enhanced cardiac magnetic resonance imaging
- Underlying heart disease:myocardial infarction, heart failure, valvular disease or cardiomyopathy
- Acute or chronic kidney failure
Key Trial Info
Start Date :
December 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04461223
Start Date
December 1 2019
End Date
December 1 2021
Last Update
July 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310000